Xvivo Perfusion AB (XVIVO) AI Stock Analysis

• Market Cap: kr6.28B
• Dividend Yield: N/A
• Average Volume (3M): 137.25K
• Price to Earnings (P/E): 210.1
• Beta (1Y): 1.31
• Revenue Growth: 8.39%
• EPS Growth: -85.36%
• Country: SE
• Employees: 193
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.26
• Shares Outstanding: 31,499,470
• 10 Day Avg. Volume: 121,914
• 30 Day Avg. Volume: 137,251
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 66 Neutral
• Price Target: kr215.00 ▲(22.16% Upside)

Xvivo Perfusion AB's overall stock score reflects strong financial health and positive earnings call sentiment, particularly in the Abdominal segment. However, technical indicators suggest potential overbought conditions, and the high P/E ratio indicates overvaluation. The company must address revenue growth and regulatory challenges to improve its stock attractiveness.

Xvivo Perfusion AB Business Overview & Revenue Model

Company Description

Xvivo Perfusion AB (XVIVO) is a Swedish medical technology company that specializes in organ preservation and perfusion solutions for transplantation. The company focuses on improving the viability of organs for transplant through innovative technologies and products, primarily targeting the fields of lung, kidney, and liver transplantation. XVIVO's core products include organ preservation solutions, perfusion devices, and associated services that enhance the effectiveness of transplant procedures and improve patient outcomes.

How the Company Makes Money

Xvivo Perfusion AB generates revenue primarily through the sale of its organ preservation solutions and perfusion devices to hospitals and transplant centers. The company has established key revenue streams from the direct sales of its products, which are designed to enhance the viability of organs during transport and storage. Additionally, XVIVO may engage in collaborations and partnerships with healthcare institutions and research organizations, providing opportunities for joint ventures and funding. The company also benefits from ongoing service contracts and training programs related to the use of its technologies, further contributing to its financial performance.

Xvivo Perfusion AB Financial Statement Overview

Summary

Xvivo Perfusion AB demonstrates strong financial health with robust gross margins and low leverage. While the company faces challenges with declining revenue growth and net profit margins, it maintains operational efficiency and a solid equity position. Cash flow metrics show improvement, but historical volatility poses a risk.

Income Statement

Xvivo Perfusion AB shows strong gross profit margins consistently above 70%, indicating efficient cost management. However, the TTM (Trailing-Twelve-Months) data reveals a decline in revenue growth rate by 3.75%, which is a concern. The net profit margin has decreased from 20.94% in 2024 to 13.53% in the TTM, reflecting reduced profitability. Despite these challenges, the company maintains a solid EBIT and EBITDA margin, demonstrating operational efficiency.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.05 in the TTM, indicating low financial leverage and a strong equity position. The return on equity has decreased slightly to 5.29% in the TTM from 7.98% in 2024, but remains positive, showing the company's ability to generate returns on shareholders' investments. The equity ratio remains healthy, reflecting a stable financial structure.

Cash Flow

Xvivo Perfusion AB has shown improvement in free cash flow growth, with a 5.03% increase in the TTM. The operating cash flow to net income ratio is 0.49, indicating moderate cash generation from operations. However, the free cash flow to net income ratio is 1.0, suggesting that all net income is being converted into free cash flow, which is a positive sign. Despite these strengths, the historical volatility in free cash flow remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	822.93M	822.41M	597.54M	415.29M	258.39M	179.86M
Gross Profit	616.09M	616.41M	445.11M	296.96M	188.28M	132.97M
EBITDA	85.98M	272.97M	126.57M	39.21M	39.20M	-43.33M
Net Income	111.38M	172.18M	91.82M	18.43M	8.15M	-43.73M
Balance Sheet
Total Assets	2.39B	2.40B	2.20B	1.73B	1.54B	1.15B
Cash, Cash Equivalents and Short-Term Investments	323.00M	415.52M	546.09M	246.54M	398.70M	353.44M
Total Debt	110.81M	34.04M	31.44M	10.01M	5.72M	7.21M
Total Liabilities	295.46M	245.97M	250.57M	302.95M	257.15M	141.85M
Stockholders Equity	2.09B	2.16B	1.95B	1.43B	1.29B	1.01B
Cash Flow
Free Cash Flow	78.51M	-81.86M	-97.65M	-103.09M	-106.13M	-76.94M
Operating Cash Flow	78.51M	111.29M	46.29M	27.86M	-12.06M	-12.27M
Investing Cash Flow	-284.20M	-243.81M	-161.62M	-197.62M	-187.70M	-266.53M
Financing Cash Flow	73.55M	-10.90M	418.55M	-6.84M	234.61M	482.77M

Xvivo Perfusion AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 176.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XVIVO, the sentiment is Positive. The current price of 176 is below the 20-day moving average (MA) of 176.97, above the 50-day MA of 174.75, and below the 200-day MA of 284.79, indicating a neutral trend. The MACD of 4.64 indicates Negative momentum. The RSI at 58.90 is Neutral, neither overbought nor oversold. The STOCH value of 55.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XVIVO.

Xvivo Perfusion AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CEVI	―	kr4.29B	28.40	18.65%	1.39%	3.45%	4.22%
VITR	―	kr20.15B	45.23	3.34%	0.75%	-1.29%	―
XVIVO	―	kr6.28B	210.07	1.32%	―	8.39%	-85.36%
GETI.B	―	kr60.82B	29.61	6.91%	2.06%	6.74%	21.40%
PAX	―	$1.58B	142.11	2.64%	―	14.28%	-68.33%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SEDANA	―	€1.05B	-25.90	-4.42%	―	13.48%	28.98%

Xvivo Perfusion AB Corporate Events

Xvivo Perfusion AB’s Mixed Earnings Call: Growth Amid Challenges

The recent earnings call for Xvivo Perfusion AB painted a mixed picture of the company’s current standing and future prospects. While there was significant growth in the Abdominal segment and strategic partnerships were formed to expand services in the U.S., challenges persist in the U.S. lung market, and there are delays in regulatory approvals for heart and liver products. This dual sentiment reflects both optimism and caution as the company navigates its complex market landscape.

XVIVO Perfusion AB Reports Mixed Financial Results for 2025

XVIVO Perfusion AB, a leading MedTech company based in Gothenburg, Sweden, specializes in developing innovative technologies for organ preservation and transplantation. The company is dedicated to extending the life of major organs such as lungs, hearts, livers, and kidneys, aiming to address the global organ shortage crisis.

XVIVO Perfusion AB Reports Mixed Financial Results Amid Strategic Investments

XVIVO Perfusion AB reported a slight decline in net sales for the first nine months of 2025, with a 1% organic growth in local currencies. The company saw significant growth in its Abdominal business area, while the Thoracic segment experienced a decline, impacting overall performance. Despite this, the company maintained a strong gross margin of 74%, and continued to invest heavily in research and development, which affected its net profit and cash flow.

The most recent analyst rating on (SE:XVIVO) stock is a Hold with a SEK188.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

XVIVO Faces Delay in CE Approval for Heart Perfusion Solution

XVIVO Perfusion AB has announced a delay in the CE approval for its heart perfusion solution, part of its heart preservation technology, due to additional consultation required by EU authorities. Despite this setback, the company’s Heart Assist Transport system has received CE approval, and recent trial results show significant improvements in patient survival, highlighting the technology’s potential impact on heart transplantation.

The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.